HIGHLIGHTS
- who: Kirsten R. Mu00fcller-Vahl from the Abbott, United States have published the research: Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial, in the Journal: (JOURNAL)
- how: The authors analyzed data on accidental and intentional unblinding from patients recruited at MHH obtained during and after the CANNA-TICS trial at both study and routine clinic visits in the center . The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.